Melanie Ivarsson, an executive at Moderna Inc, has been appointed non-executive director at LoQus23 Therapeutics Ltd, a company founded in 2019 by members of the UK Dementia Discovery Fund. LoQus23 aims to develop small molecule therapies for Huntington’s disease and other genetic disorders.
Dr Ivarsson is currently chief development officer at Moderna where she oversees clinical development programmes. In her more than 20 years in the pharmaceutical industry, she has also worked at Eli Lilly and Co, Pfizer Inc and Takeda Pharmaceutical Co Ltd.
LoQus23 Therapeutics announced the appointment on 25 January 2026.
Copyright 2022 Evernow Publishing Ltd